India, Oct. 1 -- In a major development for diabetes management and weight loss, India's drug regulator Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic (semaglutide) for use in adults with type 2 diabetes. This will make Danish drugmaker Novo Nordisk's once-a-week injection for patients available for use in the world's 'diabetes capital' on a doctor's prescription.

"Semaglutide Injection (Ozempic@) is indicated for the treatment of Adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise," the CDSCO approval read, according to ANI.

Ozempic is the brand name for semaglutide, a medication that helps control blood sugar levels in people with type 2 diabetes. It received appr...